ClinicalTrials.gg

Program

sodium phosphate

Also written as “Sodium Phosphates Injection”, “Quiklean® (sodium phosphate monobasic monohydrate, USP, and sodium phosphate dibasic anhydrous, USP)” and “Oral sodium phosphate solution”.

Its studies are led by 4 companies.

Furthest: phase 4, since Apr 23, 20135 company-led studies, 0 open or running

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Laboratoires Mayoly Spindler20 open or runningphase 3since Apr 23, 2013Jul 13, 2011none ahead
Bausch Health Companies10 open or runningphase 4since Aug 30, 2011Aug 30, 2011none ahead
Baxter Healthcare10 open or runningphase 1since Feb 11, 2025Feb 11, 2025none ahead
Universal Integrated10 open or runningphase 3since Jun 6, 2019Jun 6, 2019none ahead

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Jul 13, 2011First study: phase 2 study in ColonoscopyNew to Laboratoires Mayoly SpindlerLaboratoires Mayoly Spindler · NCT01398098 · 30 enrolled · France
  2. Aug 30, 2011Bausch Health Companies's first study: phase 4 study in Colon CleansingNew to Bausch Health CompaniesBausch Health Companies · NCT01427296 · 2,154 enrolled · United States
  3. Apr 23, 2013Phase 3 study in Colon CleansingLaboratoires Mayoly Spindler · NCT01840553 · 461 enrolled · France, Germany, Spain
  4. Jun 6, 2019Universal Integrated's first study: phase 3 study in Bowel PreparationNew to Universal IntegratedUniversal Integrated · NCT03992365 · 472 enrolled · Taiwan
  5. Feb 11, 2025Baxter Healthcare's first study: phase 1 study in HyperphagiaNew to Baxter HealthcareBaxter Healthcare · NCT06842121 · 42 enrolled · United States

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 5 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusLed byPrimary completionSize
NCT06842121Hyperphagia · United States1CompletedBaxter HealthcareMay 22, 202542
NCT03992365Bowel Preparation · Taiwan3CompletedUniversal IntegratedOct 15, 2019472
NCT01840553Colon Cleansing · France, Germany, Spain3CompletedLaboratoires Mayoly SpindlerMar 2014461
NCT01427296Colon Cleansing · United States4CompletedBausch Health CompaniesMar 11, 20142,154
NCT01398098Colonoscopy · France2CompletedLaboratoires Mayoly SpindlerMay 201230

How it is read

Names in the registry

  • “Sodium Phosphates Injection”, 1 entry
  • “Quiklean® (sodium phosphate monobasic monohydrate, USP, and sodium phosphate dibasic anhydrous, USP)”, 1 entry
  • “Oral sodium phosphate solution”, 1 entry
  • “oral sodium phosphate tablets”, 1 entry
  • “Sodium phosphate”, 1 entry

Conditions, from the studies’ own filings

    First seen by our ledger Nov 13, 2026.

    What this can’t show

    • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
    • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
    • Primary completion dates are the sponsors’ estimates and often move.
    • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.